Catalyst
Slingshot members are tracking this event:
Based on Phase 3 trial results, Vertex Pharmaceuticals expects to submit an NDA for ORKAMBI as a treatment for cystic fibrosis in patients aged 2-5 with two copies of the F508del mutation in their CFTR gene, in Q1 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VRTX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 26, 2018
Occurred Source:
https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2018-financial-results
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Orkambi, Cystic Fibrosis, Cftr
